晨间信号Morning Signal
《新科学家》 2026年10月10日 · 中文解读

迄今最强效的GLP-1疗法:三联激素组合减重效果惊人

Most potent GLP-1 therapy yet · Carissa Wong
约 7 分钟Health在小程序里点播,20 到 60 分钟做好
这篇讲什么
美国印第安纳州礼来公司的Dan Skovronsky团队招募367名超重或肥胖的2型糖尿病患者,将替尔泊肽与靶向胰淀素的药物eloralintide联用,11个月后平均减重约24.5公斤,相当于体重的23.3%。单用替尔泊肽者平均减重15.6公斤,安慰剂组仅减3%。研究者称这种方案减重幅度惊人,但腹泻、恶心等副作用更常见,EloraTZP组退出率最高达27%。
原文开头
Combining drugs that target three different appetite-suppressing hormones had an “astonishing” effect on weight loss, finds Carissa Wong THE strongest of the drugs currently approved for inducing weight loss has an even greater effect when combined with another hormone-targeting drug. The findings suggest combining the drugs could lead to more effective weight-loss therapies, an approach that could become available for wider use in the next few years. “It’s a pretty astonishing degree of weight loss,” says David Preiss at the University of Oxford, who wasn’t involved in the latest research. Tirzepatide, sold under the brand names Mounjaro and Zepbound, is the most potent approved weight-loss drug. …
摘自《新科学家》(New Scientist)2026年10月10日,Carissa Wong。仅引用开头一小段供了解文章,版权归原刊所有,全文请阅读原刊。
晨间信号小程序码
微信扫码,在小程序里听完整版
不用登录先听一篇 · 或在微信搜索小程序 晨间信号
同期其他文章